Covid-19 Sentry

Contents

From Preprints

🖺 Full Text HTML: Targeting an evolutionarily conserved “E-L-L” motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2
  1. in the blood group O and 0.43 (0.9) in the non-O group (p=0.017). There were no significant differences between A, B, and AB groups (PCS+ and PCS-) regarding inflammatory markers. In contrast, blood group O PCS+ patients had significantly higher lymphocyte count, plasma CRP, fibrinogen levels, and higher percentages of C2, C3, and C4 composite indices than PCS- subjects. The blood group O had an increased risk of developing PCS compared to non-O subjects (adjusted OR=4.20 [95%CI, 1.2-14]; p=0.023). The variables that contributed the most to the predictive model were blood group O, lymphocyte count, neutrophil count, and female sex. R-squared was 0.46, and the area under the ROC curve was 0.807 [95% CI, 0.70-0.90] (p=0.0001). Conclusion An increased risk of PCS associated with blood group O has been observed. Slightly, albeit significant, raised levels of fibrinogen, CRP, and lymphocyte count, not observed in the other ABO blood groups, have been demonstrated in blood group O. Further investigations are needed to confirm these results.

    🖺 Full Text HTML: Blood group O and post-COVID-19 syndrome

From Clinical Trials

From PubMed

From Patent Search